An interventional study of ROSE-1 Protocol in Primary Ovarian Insufficiency, Low Ovarian Reserve and Premature Ovarian Failure, sponsored by University of Illinois at Chicago. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Primary Ovarian Insufficiency with a site in United States — 10 open to participants now, 11 under way, 1 of them phase 3. Primary Ovarian Insufficiency · United States.
Among the 45 studies in Primary Ovarian Insufficiency with a site in United States, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2016, is one of 11 with no phase, and was the 28th registered.
182 studies on the registry are indexed under Primary Ovarian Insufficiency; 49 are open to participants now.
Browse Primary Ovarian Insufficiency studies →10 of the 45 studies in Primary Ovarian Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 30–40 · Women only · Healthy volunteers
University of Hawaii · Sites in United States
Ages 18+ · Women only
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 18–100
Duke University · Sites in United States
Ages 18–44 · Women only
Children's Mercy Hospital Kansas City · Sites in United States
Ages 12–20 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Primary Ovarian Insufficiency studies recruiting now, 1 (4%) sets no upper age limit and 24 (89%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 7 · Phase 4 4
First in 1991; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 48 across 114 interventional studies indexed under Primary Ovarian Insufficiency.
Median enrollment 20 across the 32 interventional studies, 72 across the 13 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 45 have an industry lead sponsor. The 10 most frequent:
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
University of Illinois at Chicago has 1 study filed under Primary Ovarian Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Primary Ovarian Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446205University of HawaiiPoi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk | 2027-01-31 |
| NCT06982677Duke UniversityImproving Outcomes in Early Menopause After Cancer | 2027-05 |
| NCT05567198National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires | 2027-05-31 |
| NCT07784582Children's National Research InstitutePre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Primary Ovarian Insufficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The ROSE-1 study is designed to determine the efficacy of bone marrow derived stem cell therapy on ovarian function recovery in subjects with idiopathic and other types of premature or primary ovarian failure (POF or POI) and low ovarian reserves.
Premature ovarian insufficiency (POI), formerly referred to as premature ovarian failure (POF), is defined as hypergonadotropic ovarian insufficiency occurring prior to age 40 (1). It is surprisingly common and affects approximately 1% of women below the age of 40 (2, 3). The incidence is 10% to 28% in women with primary amenorrhea and 4% to 18% in women with secondary amenorrhea (2). The clinical manifestations include amenorrhea and abnormally high levels of luteinizing (LH) and follicle stimulating hormone (FSH) and low levels of Anti Mullerian Hormone (AMH). The etiology of POI is unknown in most cases. It can be caused by a combination of inherited conditions such as immune disorders, environmental toxins and iatrogenic injury (2, 3). The majority of patients with POI are considered to have idiopathic premature ovarian insufficiency because usually no cause can be identified (3). POI has been shown to be associated with an increased incidence of other conditions, including Alzheimer's, cardiovascular and immune system diseases, metabolic syndrome, osteoporosis, diabetes and cancer of reproductive organs. POI is characterized by loss of secondary follicles, arrested folliculogenesis, decreased estrogen production, and infertility (3). The mechanism of ovarian insufficiency is most likely accelerated follicular atresia but detailed pathogenesis is yet to be fully understood (2).
In women younger than 40, at least two menopausal FSH levels (≥40 IU/L) will be sufficient for the diagnosis of POI. It is not essential to have amenorrhea for the diagnosis of POI. Subjects with oligomenorrhea or low ovarian reserve and elevated FSH, referred to as transitional ovarian insufficiency (TOI), or at least 4 months amenorrhea together with FSH levels exceeding 40 IU/liter, and are included in this category. Spontaneous menstrual cycles can sometimes be seen after the diagnosis of POI as well. Resumption of normal ovarian function, albeit temporary, in patients with normal karyotypes has been documented in 10 to 20% of patients; thus, spontaneous resumption of fertility is possible (1).
No therapeutic intervention has proven effective in restoring fertility in patients with POI. Currently, egg donation remains the only reliable method to establish a pregnancy in women with POI (2, 3). Even though this approach is attainable, resulting children will not be genetically related to the recipient mother. Furthermore, egg donation is not ethically acceptable to many couples. Various attempts at ovarian stimulation patients with POI are usually unsuccessful because they are poor responders. Therefore, the diagnosis of POI can cause great physical and mental suffering among these patients. Thus, there is critical need to develop novel effective approaches for the treatment of POI.
Throughout life, there is an ongoing physiological level of atresia of oocytes. A decreased germ cell endowment combined with an increased rate of germ cell destruction can explain POI (1). The current concept that the ovary has a static ovarian reserve is entirely at odds with the germ cell dynamics. Current research supports the concept that the ovary continues to produce new germ cells into adult life, however, whether this occurs in humans is not universally accepted. Recent research suggests that diminished ovarian reserve is a result of the aging of the niche rather than a defect in the germ cells (4-6). Anti-mullerian hormone has been used as a reliable biomarker for ovarian reserve in humans and the circulating AMH levels change with age as follows:
20-25: 1.23-11.51 ng/mL 26-30: 1.03-11.10 ng/mL 31-35: 0.66-8.75 ng/mL 36-40: 0.42-8.34 ng/mL 41-46: 0.26-5.81 ng/mL 47-54: \<0.82 ng/mL Emerging evidence suggests that bone marrow-derived mesenchymal stem cells (BMSCs) could restore the structure and function of injured tissues (7). During embryologic development, cells of the mesodermal layer give rise to multiple mesenchymal tissue types including bone, cartilage, tendon, muscle, and fat and marrow stroma (8). These precursor cells, also present in the postnatal organism, are referred to as mesenchymal stem cells. These stem cells have been shown to retain their developmental potential following extensive sub-cultivation in vitro. Implantation of culture-expanded mesenchymal stem cells has been demonstrated to effect tissue regeneration in a variety of animal models and depends on local factors to stimulate differentiation into the appropriate phenotype (8).
Recent studies suggest that stem cell therapy holds promise in treatment of variety of diseases including reproductive dysfunction. In a recent investigation by Ghadami et al (2012) in our lab at Augusta University in Georgia, BMSC treated animals resumed ovarian function (9). In another investigation by Lui et al (2014), granulosa cell apoptosis induced by cisplatin was reduced when BMSCs were migrated to granulosa cells in vitro. In this study, chemotherapy-induced POI rats were injected with BMSCs. The BMSCs treatment group's antral follicle count and estradiol levels increased after 30 days, compared with untreated POI group (10). In a recent clinical trial in Egypt, Edessy et al (2014) evaluated the therapeutic potential of autologous mesenchymal bone marrow stem cells transplantation in women with POI. Ten patients with POI were selected and their ovaries were injected with autologous BMSC at time of laparoscopy. The results revealed resumption of menstruation in one case after 3 months; two cases showed focal secretory changes after having atrophic endometrium (11). According to these results, BMSC seem to have the ability to revive prematurely failed ovaries both in their hormonal and follicular development abilities.
Furthermore, in this clinical trial, while at Augusta University, Georgia, USA, we have successfully initiated two cases so far (8/10/2017). Both patients have tolerated the procedure very well with no reported side effects or complications. Our first patient resumed menses after 6 months post stem cell injection and she demonstrated decreasing levels of serum FSH and increasing serum Estradiol levels (from undetectable levels pre-procedure, as well as the one week, one month and 3 months' time points assessments to 96pg/ml at the 6 months' time point (latest data available so far). She also reported amelioration of her post-menopausal symptoms including a decrease in hot flashes frequency and severity, decreased vaginal dryness and improved sleeping patterns. The second patient will be finished with the post-procedure follow up period on 2/21/2018.
Stem cell therapy has been shown to be beneficial and effective in various disease processes. The safety of the stem cell therapy has been assessed in multiple clinical trials. Although, autologous mesenchymal stem cell therapy for premature ovarian insufficiency is a novel approach, the safety and success of such stem cell therapy has been demonstrated in many other disease processes including graft versus host disease, acute myocardial infarction, acute respiratory distress syndrome (ARDS) and many other diseases (12-14). There are additional ongoing trials (Pilot -Phase III) to further assess risk and safety of stem cell based therapies (15-17). This interventional pilot clinical study will investigate the use of stem cell therapy to restore steroidogenesis, folliculogenesis, menstruation, and fertility in participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If subject is planning to pursue pregnancy: Presence of at least unilateral tubal patency (with any clinically acceptable methods).
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
Procedure: ROSE-1 Protocol
A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
Improved diagnostic hormonal levels
Reduction of 50% in FSH values; increase in AMH and Estradiol levels (30%)
Time frame: 18 months
Resumption of menses
Resumption of menses. Improved quality of life using the North American Menopausal Society (NAMS) validated menopause health questionnaire.
Time frame: 18 months
Improved clinical hormone levels
Improvement in hormonal levels toward normal ranges. Hormones may include FSH/LH; Estradiol/ progesterone;Inhibin; Anti- Mullerian Hormone
Time frame: 18 months
Achievement of pregnancy
Achievement of pregnancy by natural or assisted conception methods as may be deemed appropriate by the patient and her primary provider.
Time frame: 18 months
Ran from Feb 2016 to primary completion in May 2021, 63 months.
Of 24 interventional studies with no phase under Primary Ovarian Insufficiency, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 68. This study's 63 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Ovarian Insufficiency →
University of Illinois at Chicago →